Second Quarter 2023 Earnings

Second Quarter 2023 Key Business Highlights 6 Increasing Q2 Profitability and Gross Margin Improvement Driven by Robust VOXZOGO® Demand ☑$113 million in VOXZOGO revenues drove total BioMarin GAAP net income of $56 million and gross margin of 78.5% > Kil in the second quarter Record-breaking Revenues for the First Half of 2023, with 13% Year-Over-Year Growth Tracking to double-digit revenue growth and significant operating leverage, driving more than 30% growth in expected bottom-line profitability in full-year 2023 ROCTAVIAN ™ Approved in the U.S., the First and Only Gene Therapy for Adults with Severe Hemophilia A U.S. approval unlocks an additional 2,500 potential patients New Phase 3 Study with VOXZOGO in Second Indication (Hypochondroplasia) Announced Enrollment in the baseline, run-in arm of the study expected to begin in the fourth quarter of 2023 Uptake of VOXZOGO® Continued to Accelerate in Q2 Resulting in Increased FY23 Guidance Increased full-year 2023 guidance to between $400 million and $440 million from previous guidance of between $380 and $430 million BIOMARIN

View entire presentation